Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

NCT04945707 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Iron-deficiency
Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]
DRUG: Placebo

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]
[object Object]